Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ceribell’s FDA-cleared point-of-care EEG system with integrated AI enables rapid seizure detection and continuous monitoring in acute care. The technology has demonstrated high sensitivity and specificity for detecting status epilepticus and significantly improves diagnostic accuracy compared to clinical judgment alone. As of Q1/Q4 2024–2025, the system was used in over 500 hospitals with more than 100,000 patients monitored. The company recently expanded its FDA clearance to include pediatric use and received breakthrough device designation for delirium diagnosis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ceribell.